Building Better Chemotherapy
A $2.5-million grant from the National Cancer Institute will help the Case Comprehensive Cancer Center at the School of Medicine study ways to improve chemotherapy for glioblastoma multiforme—a common and aggressive form of brain cancer.
Bone marrow can only tolerate so many doses of chemotherapy drugs. The grant will support a new trial to explore how gene-modified stem cells might protect bone marrow from the drugs' toxicity, allowing patients to tolerate higher doses.
The trial builds on more than two decades of research by Stanton Gerson, MD, the Asa and Patricia Shiverick-Jane Shiverick (Tripp) Professor of Hematological Oncology and director of Case Comprehensive Cancer Center and the University Hospitals Seidman Cancer Center.